{"disease":{"id":"hepatic-insufficiency","name":"hepatic insufficiency"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04170309","title":"Collection of Data of Ceftobiprole Treated Patients: Comparison of Patients With and Without Certain Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":428,"lead_sponsor_name":"Advanz Pharma","has_results":false},{"nct_id":"NCT02753517","title":"Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies","phase":"NA","overall_status":"TERMINATED","enrollment_count":326,"lead_sponsor_name":"University Hospital, Lille","has_results":false},{"nct_id":"NCT03842761","title":"A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":64,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04147936","title":"Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency","phase":"NA","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"Axcella Health, Inc","has_results":false},{"nct_id":"NCT07345689","title":"A Study of the Pharmacokinetics and Safety of Anaprazole Sodium in Special Populations","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Xuanzhu Biopharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT00144248","title":"A Pharmacokinetic Study to Assess Nevirapine [Viramune] Levels in HIV Infected Patients With Impaired Hepatic Functions","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06719128","title":"A Study of Olomorasib (LY3537982) in Participants With Hepatic Impairment and Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT06957756","title":"A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":44,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT05916560","title":"A Study of LY3437943 in Participants With Impaired and Normal Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":43,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT04226833","title":"A Study to Investigate the Effect of Impaired Hepatic Function on the Pharmacokinetics of Entrectinib in Volunteers With Different Levels of Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02259855","title":"Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06190691","title":"Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT03940742","title":"A Study of Tirzepatide in Participants With Impaired Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT01797536","title":"The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03172884","title":"Study of Copanlisib in Hepatic or Renal Impairment","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Bayer","has_results":true},{"nct_id":"NCT02894385","title":"Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT05882032","title":"A Study of LY3502970 in Participants With Impaired and Normal Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT03465059","title":"Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT03341884","title":"A Study of Ipatasertib in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT05731895","title":"A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Liver Problems","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT04097704","title":"Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort","phase":"","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Celgene","has_results":false},{"nct_id":"NCT05661344","title":"A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT02334800","title":"A Study To Describe The Effect Of Impaired Hepatic Function Of The Pharmacokinetics Of Palbociclib","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":28,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05440344","title":"A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Eli Lilly and Company","has_results":true},{"nct_id":"NCT06390410","title":"A Pharmacokinetic Study of Simufilam in Subjects With Impaired Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Cassava Sciences, Inc.","has_results":false},{"nct_id":"NCT03306667","title":"Clinical Pharmacology of FYU-981 (Subjects With Hepatic Insufficiency)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Mochida Pharmaceutical Company, Ltd.","has_results":false},{"nct_id":"NCT02249442","title":"Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04993404","title":"Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT06620731","title":"Clinical Trial of FCN-437c Capsule in Patients With Hepatic Insufficiency","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Ahon Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06176716","title":"Phase 1 Hepatic Insufficiency Trial of Methoxyethyl Etomidate Hydrochloride","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"Ahon Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07055412","title":"Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":24,"lead_sponsor_name":"Neurodawn Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT05093972","title":"Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":22,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT06575959","title":"A Clinical Study of Enlicitide Decanoate in People With Liver Function Problems (MK-0616-030)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT04867941","title":"A Study to Evaluate the Effect of Hepatic Insufficiency on the Pharmacokinetics (PK) of ACP-196","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Acerta Pharma BV","has_results":false},{"nct_id":"NCT07102095","title":"A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT01512693","title":"Assessment of Pharmacokinetics of Single Dose Odanacatib (MK-0822) in Participants With Moderate Hepatic Insufficiency (MK-0822-070)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT01043926","title":"Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT03968848","title":"Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Acerta Pharma BV","has_results":true},{"nct_id":"NCT07049939","title":"A Study of Bomedemstat (MK-3543) in Participants With Mild or Moderate Hepatic Impairment (MK-3543-023)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":9,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT03295266","title":"Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05209295","title":"A Study to Evaluate CC-486/Onureg in Participants With Moderate or Severe Hepatic Impairment Compared With Normal Hepatic Function in Participants With Myeloid Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":2,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false}],"total":41},"guidelines":[],"source":"Drug Landscape verified database"}